Chief executive of AstraZeneca Pascal Soriot leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London May 13, 2014. US drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs.

London - British drugs company AstraZeneca said its bigger US rival Pfizer was making an “opportunistic attempt” to buy the company for a price that didn't reflect the value of its “exciting pipeline” of new drugs.

In response to an appeal from Pfizer for it to enter negotiations, AstraZeneca said Pfizer's announcement on Tuesday contained no new proposal nor substantive new information. - Reuters